ARM · NASDAQ-GS
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Total Revenue | $4.92B | $4.01B | $3.23B | $2.68B | $2.70B |
| Cost of Revenue | $121.00M | $121.00M | $154.00M | $106.00M | $131.00M |
| Gross Profit | $4.80B | $3.89B | $3.08B | $2.57B | $2.57B |
| Research & Development | $2.78B | $2.07B | $1.98B | $1.13B | $995.00M |
| Selling, General & Administrative | $1.11B | $984.00M | $983.00M | $762.00M | $897.00M |
| Operating Expenses | $3.90B | $3.06B | $2.97B | $1.90B | $1.94B |
| Operating Income | $900.00M | $831.00M | $111.00M | $671.00M | $633.00M |
| Other Income / (Expense) | $132.00M | $10.00M | $11.00M | $3.00M | $10.00M |
| Income Before Taxes | $1.16B | $720.00M | $212.00M | $671.00M | $786.00M |
| Provision for Income Taxes | $253.00M | -$72.00M | -$94.00M | $146.80M | $109.70M |
| Net Income | $904.00M | $792.00M | $306.00M | $524.00M | $549.00M |
| Basic EPS | $0.85 | $0.75 | $0.30 | $0.51 | $0.54 |
| Diluted EPS | $0.85 | $0.75 | $0.29 | $0.51 | $0.54 |
| Basic Shares Outstanding | 1.06B | 1.05B | 1.03B | 1.02B | 1.03B |
| Diluted Shares Outstanding | 1.07B | 1.06B | 1.04B | 1.03B | 1.03B |
| Period | Consensus EPS | Low | High | Estimates | Revisions |
|---|---|---|---|---|---|
| Mar 2027 | $1.15 | $0.90 | $1.42 | 8 | ↑3 ↓1 |
| Mar 2028 | $1.94 | $1.40 | $2.38 | 7 | ↑3 ↓1 |
| Mar 2029 | $2.73 | $2.30 | $3.53 | 3 | ↑1 ↓2 |
| Mar 2030 | $4.05 | $4.05 | $4.05 | 1 | ↑0 ↓1 |